The Study is Being Conducted to Find a New Treatment for Patients Suffering From Interstitial Cystitis With Hunner's Lesions

Inclusion criteria

• Written informed consent prior to any study-related procedures.
• Women aged 18 to 65 years, inclusive.
• A confirmed diagnosis of painful bladder syndrome/interstitial cystitis, characterized by pelvic pain associated with filling or emptying the bladder, frequent urination day and night, with symptoms lasting at least 12 months, with the exclusion of a urinary tract infection or other disease that could cause such symptoms.
• The presence of Hunner's lesions of the bladder during cystoscopy with hydrobougienage of the bladder (2 minutes, 80 cm H2O).
• A glycated hemoglobin level within the normal range for the patient's age group.
• Ability to comply with all study requirements, in the opinion of the investigator, including regularly keeping a voiding diary, completing questionnaires, and attending all scheduled study visits.
• Women who are of childbearing potential must have negative pregnancy test results and must use reliable contraception throughout their participation in the study.

Exclusion criteria

• Any condition that prevents intravesical administration of medications.
• Received medication or non-medication therapy, including physical therapy, for BPS/IC within 1 month prior to study inclusion.
• Instillation of any pharmacological agent into the bladder less than 1 month prior to screening.
• History of chronic drug or alcohol abuse.
• Pregnant women, planning to become pregnant during the study, or currently breastfeeding.
• Any other conditions associated with pelvic pain, except for PBS.
• Pelvic surgery less than 6 months prior to the study.
• Any intravesical procedures, except for diagnostic cystoscopy, less than 3 months prior to screening.
• History of allergy or intolerance to the anesthetic or antibiotics that the investigator intends to use during the study.
• Inability to discontinue anticoagulant/antiplatelet medications at least 5 days prior to each investigational drug administration and resume them on the 4th day after each investigational drug administration (low molecular weight heparin may be used for 3 days after investigational drug administration).
• Diseases of the urinary tract/bladder (neoplasms, tuberculous and bacterial cystitis, urolithiasis, radiation injury, urethral diverticulum, neurogenic dysfunction of the lower urinary tract) and female genital organs (neoplasms, vaginitis, genital infections).
• Other conditions that, in the opinion of the research physician, could become an objective obstacle to the patient's participation in the study and/or create additional risks for the patient.
• A history of intravesical botulinum therapy performed within the last 12 months prior to inclusion in this study.
• Bladder capacity under anesthesia less than 150 ml.
• Residual urine volume greater than 50 ml.